80 related articles for article (PubMed ID: 38285120)
1. Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma.
Minskaia E; Maimaris J; Jenkins P; Albuquerque AS; Hong Y; Eleftheriou D; Gilmour KC; Grace R; Moreira F; Grimbacher B; ; Morris EC; Burns SO
J Clin Immunol; 2023 Oct; 43(7):1611-1622. PubMed ID: 37316763
[TBL] [Abstract][Full Text] [Related]
2. Single-cell transcriptome sequencing provides insight into multiple chemotherapy resistance in a patient with refractory DLBCL: a case report.
Zhao K; Li Q; Li P; Liu T; Liu X; Zhu F; Zhang L
Front Immunol; 2024; 15():1303310. PubMed ID: 38533514
[TBL] [Abstract][Full Text] [Related]
3. Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma.
Cerchietti L
Blood; 2024 Mar; 143(12):1101-1111. PubMed ID: 38211334
[TBL] [Abstract][Full Text] [Related]
4. Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications.
Almasmoum HA
J Appl Genet; 2024 Feb; 65(1):57-72. PubMed ID: 38001281
[TBL] [Abstract][Full Text] [Related]
5. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
6. STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment.
Benoit A; Abraham MJ; Li S; Kim J; Estrada-Tejedor R; Bakadlag R; Subramaniam N; Makhani K; Guilbert C; Tu R; Salaciak M; Klein KO; Coyle KM; Hilton LK; Santiago R; Dmitrienko S; Assouline S; Morin RD; Del Rincon SV; Johnson NA; Mann KK
Int J Hematol; 2024 Mar; 119(3):275-290. PubMed ID: 38285120
[TBL] [Abstract][Full Text] [Related]
7. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
Morin RD; Assouline S; Alcaide M; Mohajeri A; Johnston RL; Chong L; Grewal J; Yu S; Fornika D; Bushell K; Nielsen TH; Petrogiannis-Haliotis T; Crump M; Tosikyan A; Grande BM; MacDonald D; Rousseau C; Bayat M; Sesques P; Froment R; Albuquerque M; Monczak Y; Oros KK; Greenwood C; Riazalhosseini Y; Arseneault M; Camlioglu E; Constantin A; Pan-Hammarstrom Q; Peng R; Mann KK; Johnson NA
Clin Cancer Res; 2016 May; 22(9):2290-300. PubMed ID: 26647218
[TBL] [Abstract][Full Text] [Related]
8. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.
Lu X; Chen J; Sasmono RT; Hsi ED; Sarosiek KA; Tiganis T; Lossos IS
Mol Cell Biol; 2007 Mar; 27(6):2166-79. PubMed ID: 17210636
[TBL] [Abstract][Full Text] [Related]
9. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
[TBL] [Abstract][Full Text] [Related]
10. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.
Guiter C; Dusanter-Fourt I; Copie-Bergman C; Boulland ML; Le Gouvello S; Gaulard P; Leroy K; Castellano F
Blood; 2004 Jul; 104(2):543-9. PubMed ID: 15044251
[TBL] [Abstract][Full Text] [Related]
11. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
Ritz O; Guiter C; Castellano F; Dorsch K; Melzner J; Jais JP; Dubois G; Gaulard P; Möller P; Leroy K
Blood; 2009 Aug; 114(6):1236-42. PubMed ID: 19423726
[TBL] [Abstract][Full Text] [Related]
12. Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns.
Dreval K; Hilton LK; Cruz M; Shaalan H; Ben-Neriah S; Boyle M; Collinge B; Coyle KM; Duns G; Farinha P; Grande BM; Meissner B; Pararajalingam P; Rushton CK; Slack GW; Wong J; Mungall AJ; Marra MA; Connors JM; Steidl C; Scott DW; Morin RD
Blood; 2023 Aug; 142(6):561-573. PubMed ID: 37084389
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of Adenosine-to-Inosine RNA editing-based subtypes and novel risk score for the prognosis and drug sensitivity in stomach adenocarcinoma.
Pan J; Gu X; Luo J; Qian X; Gao Q; Li T; Ye L; Li C
Front Cell Dev Biol; 2022; 10():1073688. PubMed ID: 36531956
[TBL] [Abstract][Full Text] [Related]
14. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.
Albanyan O; Chavez J; Munoz J
Ther Adv Hematol; 2022; 13():20406207221141511. PubMed ID: 36505886
[TBL] [Abstract][Full Text] [Related]
15. PARP14 is a novel target in STAT6 mutant follicular lymphoma.
Mentz M; Keay W; Strobl CD; Antoniolli M; Adolph L; Heide M; Lechner A; Haebe S; Osterode E; Kridel R; Ziegenhain C; Wange LE; Hildebrand JA; Shree T; Silkenstedt E; Staiger AM; Ott G; Horn H; Szczepanowski M; Richter J; Levy R; Rosenwald A; Enard W; Zimber-Strobl U; von Bergwelt-Baildon M; Hiddemann W; Klapper W; Schmidt-Supprian M; Rudelius M; Bararia D; Passerini V; Weigert O
Leukemia; 2022 Sep; 36(9):2281-2292. PubMed ID: 35851155
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
